Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination

The summary for the Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control NCIRD, which is the U.S. government agency offering this grant.

Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination: The purpose of this cooperative agreement is to: (1). Advance a national network of cancer prevention organizations, immunization partners, and other stakeholders by creating and supporting a planning committee that prioritizes network activities, updates and disseminates educational resources, and expands the diversity of organizations represented within the network that positively impact HPV vaccination rates; (2). Convene a national meeting of network members to provide technical assistance and catalyze their support of efforts to increase HPV vaccine uptake; and (3). Create and support task groups to address priority areas identified by the national network, initiate high-priority pilot projects to reduce barriers to HPV vaccine uptake, and share lessons learned. By working toward these goals, the network can provide channels of education, outreach, and training structured for the public and healthcare providers. The network, through its engagement and coordination with stakeholders, will be equipped to increase public and provider understanding of the burden of HPV-associated cancers that can be prevented by HPV vaccination and to accelerate the full implementation of HPV vaccination to prevent HPV-associated cancers.